CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases. Our mission is to alleviate human suffering and improve patients' quality of life through innovation and collaboration. We are committed to performing our duties with respect, integrity, and a unified vision of serving humanity.
CytoDyn is a clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is being studied for oncology and inflammation, as well as other potential indications, including but not limited to HIV and MASH. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. We believe this mechanism of action, of binding competitively to the CCR5 receptor, differentiates leronlimab from all other CCR5 antagonists.
